Malaria is a serious threat to human life, and with the increase of drug resistance of Plasmodium, this crisis may lead to disaster. Therefore, there is an urgent need to develop drugs that can effectively target and have high bioavailability for treatment. CD BioSciences provides comprehensive peptidomimetic development services with anti-malarial activity to help customers worldwide in basic research and drug discovery in antimalarial.
Overview of Malaria
Malaria is a parasitic disease common in many tropical and subtropical regions of the world and is mainly transmitted by mosquitoes. Millions of people die each year due to recurrence of the disease and lack of proper treatment. The four species of Plasmodium species known to infect humans are P. falciparum, P. vivax, P. ovale, and P. malaria. Of these, P. falciparum is responsible for the most severe form of malaria infection. Existing malaria treatments include a limited number of clinical drugs, but with the rise of widespread parasite resistance, there is an urgent need to discover new and effective anti-malarial therapies and drugs.
Fig. 1 Pictorial representation of glycation. (Phillips, et al., 2017)
Disadvantages of Anti-Malarial Peptides
Anti-malarial peptides with different size, sequence, charge, structure, hydrophobicity and amphiphilicity reflect their heterogeneity in anti-malarial activity, and their unique mechanism of action can delay the occurrence of drug resistance. Although anti-malarial peptides show significant antimalarial advantages, there are still few clinical anti-malarial peptide drugs available. The reason is that the bioavailability of the currently developed anti-malarial peptides is extremely low, and most peptides that show activity in cultured parasitic red blood cells have no therapeutic effect in vivo models.
Therefore, it is of great significance to develop highly stable anti-malarial peptidomimetics, which will be the lead compounds of anti-malarial drugs with expected efficacy and safety, and make great contributions to human malaria treatment.
Fig. 2 Evolution of CAAX peptidomimetic PFT inhibitors. (Carrico, et al., 2004)
Our Services
CD BioSciences provides comprehensive peptidomimetic development services with anti-malarial activity. In view of several major defects of current anti-malarial peptides:
PepDomTM can provide professional solutions and measures to solve the above deficiencies. The peptidomimetic compounds developed using our unique technology meet all the cutting-edge needs of global customers based on anti-malarial peptide drug development.
The services we provide include but are not limited to:
- Cationic 'Host-Defence' Peptidomimetics Development
- Miscellaneous Peptidomimetics Development
- Hydrophobic Peptidomimetics Development
- Other Membrane-Active Peptidomimetics Development
- Thiopeptides Development
- Related Peptidase Substrate Analogs Development
Advantages of Our Peptidomimetics
|
High Ability: with broad protease resistance
|
|
High Anti-malarial activity: targeting specific sites of action
|
|
Broad Action: resistant to more than one type of Plasmodium
|
|
Low Side Effects: the specific route works without causing other side effects
|
CD BioSciences focuses on developing peptidomimetics with anti-malarial activity. As long as you provide the objectives and research directions you are interested in, our professional team will immediately provide you with professional solutions and measures. Welcome to contact us for the best solution.
References
- Phillips, M. A., Burrows, J. N., Manyando, C., et al. (2017). Malaria. Nature Reviews Disease Primers, 3, 17050.
- Carrico, D., Ohkanda, J., Kendrick, H., et al. (2004). In vitro and in vivo antimalarial activity of peptidomimetic protein farnesyltransferase inhibitors with improved membrane permeability. Bioorganic & Medicinal Chemistry, 12(24), 6517–6526.
All of our services are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
